Latest News

On March 6, 2024, the FDA approved inotuzumab ozogamicin for pediatric patients with relapsed/refractory CD22-positive B-cell precursor acute lymphoblastic leukemia.

The combination of all-trans retinoic acid and arsenic trioxide with or without gemtuzumab ozogamicin and idarubicin is a highly effective salvage therapy for patients with relapsed acute promyelocytic leukemia, according to a recent study.

According to a real-world analysis, doxorubicin, vinblastine, and dacarbazine demonstrates a highly efficacy for patients with advanced stage classic Hodgkin lymphoma, including those with prominent dose reductions or omission of brentuximab...

Mutational status predicted survival outcomes among patients with clonal cytopenia without a confirmed hematological diagnosis who had undergone bone marrow examination, according to findings from a prospective cohort study.

According to a retrospective analysis, azacitidine maintenance is associated with a lower progression rate in patients with high-risk FLT3-negative acute myeloid leukemia or myelodysplastic syndrome.

According to a phase 3 trial, adding daratumumab to bortezomib, lenalidomide, and dexamethasone therapy and to lenalidomide maintenance therapy yielded beneficial outcomes among transplantation-eligible patients with newly diagnosed multiple...

According to a long-term follow-up of the LYMA trial, rituximab maintenance following autologous stem cell transplantation continued to demonstrate benefits to efficacy and safety outcomes among first-line patients with mantle cell lymphoma.

Advances in prognostic models can help guide treatment strategy for patients with mantle cell lymphoma, according to an analysis by The North American Mantle Cell Lymphoma Consortium.

Final, updated results from the phase 3 POUT trial added further support to the use of adjuvant chemotherapy for patients with upper tract urothelial cancer who have undergone nephroureterectomy.